No. Level of Risk Gene Mutations Gene Fusion Treatment Methods D15 MRD D33 MRD Current Condition
ALL-1 Intermediate risk No No Chemotherapy 6.2×10^-2 5.0×10^-4 In chemotherapy
ALL-2 Low risk IKZF1, KMT2C, ASXL3, SMC1A No Chemotherapy - 1.32×10-6 Drug withdrawal for one year
ALL-3 Intermediate risk TP53, RB1, PIK3CD, USH2A No Chemotherapy 1.0×10-3 Negative In chemotherapy
ALL-4 High risk INRAS, KRAS, CSMD1, SOS1 No Chemotherapy 3.0×10^e-3 2.1×10e-4 In chemotherapy
ALL-5 Intermediate risk CREBBP, KRAS, IRF8, TBL1XR1 SPI1::ZNF384 Chemotherapy + blinatumomab 2.0×10^e-2 8.0×10^e-5 In chemotherapy
ALL-6 Intermediate risk NRAS, FLT3, IKZF3 DUX4::lgHJ6(582) Chemotherapy 5.5×10^e-3 Negative In chemotherapy
ALL-7 Intermediate risk No No Chemotherapy 1.0×10^e-4 Negative In chemotherapy
ALL-8 Intermediate risk FLT3, PTPN11, KRAS, ETV6 EP300-ZNF384 Chemotherapy 7.2×10e-3 4×10^e-5 In chemotherapy
ALL-9 Intermediate risk NRAS, KRAS No Chemotherapy 2.2×10^e-3 Negative In chemotherapy
ALL-10 High risk NRAS, KRAS, CREBBP No Chemotherapy + blinatumomab 1.3×10^e-2 Negative In chemotherapy
ALL-11 Intermediate risk No TEL-AML1 Chemotherapy 5.8×10^e-3 4×10^e-5 In chemotherapy
ALL-12 Intermediate risk ASXL1, ATRX, CHD2 EP300-ZNF384 Chemotherapy 2.0×10^e-4 Negative In chemotherapy